Live Analyst Rating Changes 1515 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kyle Bauser
ROTH
Kyle Bauser
Wall Street Analyst
★☆☆☆☆
#2495
on 13Foresight · ranked by our own returns
27%
Success Rate
-11.4%
Average Return
9 of 33 calls profitable · -17.7% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 27% of Kyle Bauser's ratings turned a profit when each position was held for 1 year — averaging -11.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

63 Buy 0 Hold 0 Sell
Kyle's Stock Coverage 40 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
SNWV
Sanuwave Health
Apr 17, 2026 BUY Strong Buy
+270.4% avg upside
3 analysts
$47.00
410.37% Upside
-18.2%
CV
CapsoVision, Inc.
Apr 14, 2026 BUY Strong Buy
+36.2% avg upside
3 analysts
$11.00
66.32% Upside
-0.6%
BEAT
HeartBeam
Apr 14, 2026 BUY Buy
+469.4% avg upside
13 analysts
$4.00
426.57% Upside
-34.4%
TSE:AIDX
HEALWELL AI
Apr 14, 2026 BUY Strong Buy
+182.2% avg upside
8 analysts
$2.50
201.16% Upside
·
SPRY
ARS Pharmaceuticals
Apr 14, 2026 BUY Strong Buy
+121.7% avg upside
12 analysts
$30.00
210.82% Upside
-8.7%
MBOT
Microbot Medical
Apr 14, 2026 BUY Strong Buy
+259.6% avg upside
7 analysts
$5.50
195.60% Upside
-29.6%
AURX
Nuo Therapeutics
Apr 14, 2026 BUY Strong Buy
+231.5% avg upside
1 analyst
$3.00
231.51% Upside
·
APYX
Apyx Medical
Apr 14, 2026 BUY Strong Buy
+613.1% avg upside
10 analysts
$6.00
45.92% Upside
+10.9%
STXS
Stereotaxis
Apr 14, 2026 BUY Strong Buy
+127.1% avg upside
7 analysts
$4.00
112.69% Upside
-12.3%
LMAT
Lemaitre Vascular
Feb 26, 2026 BUY Strong Buy
+8.3% avg upside
15 analysts
$117.00
24.54% Upside
-18.8%
INFU
InfuSystem Holdings
Feb 25, 2026 BUY Strong Buy
+62.1% avg upside
7 analysts
$15.00
59.15% Upside
+6.8%
ELMD
Electromed
Feb 20, 2026 BUY Strong Buy
-14.4% avg upside
6 analysts
$38.00
1.74% Downside
+3.5%
IRMD
Iradimed
Feb 11, 2026 BUY Strong Buy
-9.2% avg upside
6 analysts
$120.00
30.09% Upside
-15.6%
VREX
Varex Imaging
May 13, 2025 BUY Strong Buy
+94.0% avg upside
9 analysts
$12.00
13.92% Upside
+34.3%
SPOK
Spok Holdings
Feb 27, 2025 BUY Strong Buy
+65.8% avg upside
3 analysts
$20.00
90.34% Upside
-22.3%
TCMD
Tactile Systems Technology
Feb 19, 2025 HOLD Strong Buy
+55.5% avg upside
8 analysts
$18.00
32.35% Downside
+82.4%
CLPT
ClearPoint Neuro
Jan 28, 2025 BUY Strong Buy
+4.7% avg upside
7 analysts
$20.00
12.64% Upside
-25.1%
OPRX
OptimizeRx
Dec 23, 2024 BUY Strong Buy
+158.1% avg upside
9 analysts
$13.00
161.03% Upside
+163.8%
LFMD
LifeMD
Nov 08, 2024 BUY Strong Buy
+145.1% avg upside
13 analysts
$12.00
152.67% Upside
-10.4%
KRMD
REPRO-MED Systems
Jul 25, 2024 BUY Strong Buy
+64.8% avg upside
9 analysts
$4.00
2.64% Upside
+39.2%
OBIO
Orchestra BioMed Holdings
Jul 24, 2024 BUY Strong Buy
+234.3% avg upside
9 analysts
$15.00
275.99% Upside
-59.8%
UFPT
Ufp Technologies
Nov 03, 2022 BUY Strong Buy
-20.8% avg upside
7 analysts
$124.00
48.18% Downside
+32.4%
BIOLQ
BIOLASE
May 20, 2022 BUY Strong Buy
+1197999900.0% avg upside
6 analysts
$12.00
1199999899.97% Upside
·
MRMD
MariMed
Mar 18, 2022 BUY Strong Buy
+1281.0% avg upside
3 analysts
$2.25
3114.33% Upside
-41.3%
LTRN
Lantern Pharma
Mar 11, 2022 BUY Strong Buy
+491.8% avg upside
5 analysts
$29.00
665.16% Upside
-37.1%
MYO
Myomo
Mar 10, 2022 BUY Strong Buy
+464.7% avg upside
9 analysts
$17.00
1228.10% Upside
-83.0%
SENS
Senseonics Holdings
Mar 02, 2022 BUY Buy
+125.2% avg upside
13 analysts
$3.00
55.45% Downside
-50.5%
ASTH
Astrana Health
Feb 25, 2022 BUY Strong Buy
+37.0% avg upside
16 analysts
$93.00
137.40% Upside
-29.8%
MOTS
Motus Gi Holdings
Feb 14, 2022 BUY Buy
+49433233.3% avg upside
6 analysts
$50.00
49999899.93% Upside
·
NOTVQ
Inotiv
Feb 11, 2022 BUY Strong Buy
+179095.3% avg upside
6 analysts
$74.00
510244.75% Upside
·
BMRA
Biomerica
Feb 08, 2022 BUY Strong Buy
+626.3% avg upside
1 analyst
$13.00
626.30% Upside
-32.5%
AU:IPD
Impedimed Limited
Jan 20, 2022 BUY Strong Buy
+2650.0% avg upside
2 analysts
$0.27
4399.90% Upside
·
IVF
INVO Fertility
Nov 16, 2021 BUY Strong Buy
+155.6% avg upside
3 analysts
$6.00
300.04% Upside
-61.7%
INSP
Inspire Medical Systems
Apr 29, 2021 BUY Buy
+98.0% avg upside
20 analysts
$266.00
524.24% Upside
-14.5%
DHC
Diversified Healthcare Trust
Feb 26, 2021 HOLD Buy
+24.9% avg upside
11 analysts
-32.8%
CHCT
Community Healthcare
Feb 17, 2021 BUY Buy
+97.4% avg upside
12 analysts
$55.00
215.48% Upside
-3.6%
MPT
Medical Properties Trust
Feb 05, 2021 BUY Hold
+162.9% avg upside
24 analysts
$24.00
429.86% Upside
·
NDRA
ENDRA Life Sciences
Jun 13, 2019 BUY Strong Buy
+156.7% avg upside
3 analysts
$5.00
5.10% Upside
-48.5%
DMAC
Diamedica Therapeutics
Apr 30, 2019 BUY Strong Buy
+153.7% avg upside
12 analysts
$8.00
36.82% Upside
+19.3%
MBAI
Check-Cap
Feb 05, 2019 BUY Strong Buy
+482.7% avg upside
5 analysts
$6.00
319.58% Upside
·
🔒 35 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Kyle Bauser — Frequently Asked Questions
How accurate are Kyle Bauser's stock ratings?
Based on the calls 13Foresight could measure, about 27% of Kyle's ratings were profitable over a one-year hold, with an average return of -11.4% per rating, or -17.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Kyle ranked on 13Foresight?
Kyle Bauser is currently ranked #2495 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kyle cover?
Kyle most recently has ratings on SNWV, CV, BEAT, TSE:AIDX, SPRY, MBOT, AURX, APYX, STXS, LMAT, INFU, ELMD and 28 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.